title: Leukemia inhibitory factor: a novel bone-active cytokine.
abstract: A number of cytokines have been found to be potent regulators of bone resorption and to share the properties originally attributed to osteoclast-activating factor. One such activity, differentiation-inducing factor (DIF, D-factor) from mouse spleen cells, shares a number of biological and biochemical properties with the recently characterized and cloned leukemia inhibitory factor (LIF). We have assessed the effects of recombinant LIF on bone resorption and other parameters in neonatal mouse calvaria. Both recombinant murine and human (h) LIFs stimulated 45Ca release from prelabeled calvaria in a dose-dependent manner. The increase in bone resorption was associated with an increase in the number of osteoclasts per mm2 bone. The osteolytic effect of hLIF were blocked by 10(-7) M indomethacin. hLIF also stimulated incorporation of [3H] thymidine into calvaria, but the dose-response relationship was distinct from that for bone resorption, and this effect was not blocked by indomethacin. Similarly, hLIF increased [3H]phenylalanine incorporation into calvaria, and this was also not inhibited by indomethacin. It is concluded that LIF stimulates bone resorption by a mechanism involving prostaglandin production, but that a distinct mechanism is responsible for its stimulation of DNA and protein synthesis. The primary structure of LIF differs from that of other fully characterized, bone-active cytokines, and it, thus, represents a novel factor which may be involved in the normal regulation of bone cell function.
authors.affiliation: Department of Medicine, University of Auckland, New Zealand.
authors.forename: L R
authors.initials: LR
authors.lastname: Reid
authors.forename: C
authors.initials: C
authors.lastname: Lowe
authors.forename: J
authors.initials: J
authors.lastname: Cornish
authors.forename: S J
authors.initials: SJ
authors.lastname: Skinner
authors.forename: D J
authors.initials: DJ
authors.lastname: Hilton
authors.forename: T A
authors.initials: TA
authors.lastname: Willson
authors.forename: D P
authors.initials: DP
authors.lastname: Gearing
authors.forename: T J
authors.initials: TJ
authors.lastname: Martin
mesh_terms: D000818:Animals; D001685:Biological Factors / Q000494:pharmacology*; D001862:Bone Resorption / Q000503:physiopathology; D001842:Bone and Bones / Q000187:drug effects*; D002118:Calcium / Q000378:metabolism; D016207:Cytokines; D004305:Dose-Response Relationship, Drug; D006131:Growth Inhibitors / Q000494:pharmacology*; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D015850:Interleukin-6; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines; D051379:Mice; D010649:Phenylalanine / Q000378:metabolism; D012886:Skull / Q000187:drug effects / Q000378:metabolism; D013936:Thymidine / Q000378:metabolism
chemical_list: D001685:Biological Factors; D016207:Cytokines; D006131:Growth Inhibitors; D015850:Interleukin-6; C507837:LIF protein, human; D053605:Leukemia Inhibitory Factor; C507838:Lif protein, mouse; D008222:Lymphokines; D010649:Phenylalanine; D002118:Calcium; D013936:Thymidine; D007213:Indomethacin